NxStage Dialysis Needle Technology Gets FDA Nod
This article was originally published in The Gray Sheet
Executive Summary
The company says its new needle technology means patients will only need to be pricked once during a dialysis procedure instead of twice which will reduce their discomfort while preserving vascular access.
You may also be interested in...
News Briefs: Teleflex Acquires Vidacare; Integra Buys Covidien’s DuraSeal Line
Teleflex buys Vidacare Corp. for $262.5 million. Integra LifeSciences acquires Covidien’s Confluent Surgical product line, including the DuraSeal products, for $235 million, plus up to $30 million in milestone payments. W.L. Gore ordered to pay more than $850 million to C.R. Bard to partially resolve a long-running patent dispute. More news.
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?